Two FDA-approved drugs for the symptomatic treatment of HD-mediated chorea, tetrabenazine and deutetrabenazine, target the dopaminergic pathway through inhibition of the vesicular monoamine transporter (VMAT2 inhibitor), resulting in decreased bioavailability of dopamine in synapses and reduced dopamine signalling. The gene discussed is SLC18A2; the disease is choreatic disease.